Glassia: Phase II started

Kamada and Baxalta began an open-label, Israeli Phase II trial to compare IV Glassia plus the standard of care

Read the full 196 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE